These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3892706)

  • 21. Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia.
    Capizzi RL; Powell BL; Cooper MR; Stuart JJ; Muss HB; Richards F; Jackson DV; White DR; Spurr CL; Zekan PJ
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):105-13. PubMed ID: 3892697
    [No Abstract]   [Full Text] [Related]  

  • 22. Low doses of Ara-C in chronic myeloid leukemia in blastic transformation.
    Di Raimondo F; Guglielmo P; Milone G; Cacciola E; Giustolisi R
    Haematologica; 1985; 70(3):274-6. PubMed ID: 3932167
    [No Abstract]   [Full Text] [Related]  

  • 23. Assay of cell resistance to ara-C.
    Lacombe F
    Methods Cell Biol; 1994; 42 Pt B():45-58. PubMed ID: 7533251
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of autoradiography and DNA histograms in assessing S-phase cells from patients with myeloid leukemias.
    Raza A; Raza AS; Kuliczkowski K; Zhao SC; Preisler HD
    Med Oncol Tumor Pharmacother; 1985; 2(4):269-79. PubMed ID: 3866897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Results of therapy with high-dose cytosine arabinoside].
    Pralle H; Breithaupt H
    Onkologie; 1985 Feb; 8(1):48, 50-2. PubMed ID: 3885122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.
    Minderman H; O'Loughlin KL; Smith PF; Pendyala L; Greco WR; Sweeney KG; Ford LA; Wetzler M; Baer MR
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):73-83. PubMed ID: 16010591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
    Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
    Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Successful treatment with low-dose Ara-C in a case of chronic myelomonocytic leukemia].
    Gotoh T; Takeda N; Itoh K; Fujita N; Shimazaki C; Nakanishi S; Nakagawa M; Ijichi H; Nishio A; Haruyama H
    Rinsho Ketsueki; 1987 Apr; 28(4):583-8. PubMed ID: 3476766
    [No Abstract]   [Full Text] [Related]  

  • 30. [The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of relapsing or refractory cases of acute myelogenous leukemia].
    Kawano F; Tejima Y; Tajima H; Lee SY; Shiozaki A; Nakai R; Chyosa M; Sawada T; Maeda Y; Mizokuni T
    Rinsho Ketsueki; 1986 Mar; 27(3):315-20. PubMed ID: 3461178
    [No Abstract]   [Full Text] [Related]  

  • 31. Double labeling of human leukemic cells using 3H-cytarabine and monoclonal antibody against bromodeoxyuridine.
    Raza A; Preisler HD
    Cancer Treat Rep; 1985 Feb; 69(2):195-8. PubMed ID: 3882228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Subleukemic acute monophagocytic leukemia. A biological phenotype close to malignant histiocytosis].
    Sánchez Fayos J; Pérez Sáenz MA; Benítez J; Outeiriño J; Prieto E; Calabuig T; Rodríguez C
    Sangre (Barc); 1991 Oct; 36(5):427-30. PubMed ID: 1816640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
    Riva CM; Rustum YM; Preisler HD
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925
    [No Abstract]   [Full Text] [Related]  

  • 34. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT; Jiang SY; Li BS; Yang LL
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of small doses cytosine arabinoside (Ara-C) on leukemic cells in vitro and in vivo. Results in patients with leukemia and myelodysplastic syndrome.
    Kuliczkowski K; Kotlerek-Haus S; Frydecka I; Sedek K; Nowicka J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):738-48. PubMed ID: 2436986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
    te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
    Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose cytosine arabinoside in the treatment of acute nonlymphoblastic leukemia and myelodysplastic syndromes.
    Hoelzer D; Ganser A; Schneider W; Heimpel H
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):208-11. PubMed ID: 4012339
    [No Abstract]   [Full Text] [Related]  

  • 38. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement.
    Castagnola C; Nozza A; Corso A; Bernasconi C
    Haematologica; 1997; 82(5):577-80. PubMed ID: 9407724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
    Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Central nervous system (CNS) leukemia: the role of high dose cytarabine (HDAra-C).
    Morra E; Lazzarino M; Alessandrino EP; Inverardi D; Regazzi Bonora M; Pagnucco G; Orlandi E; Bernasconi P; Canevari A; Rondanelli R
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():101-3. PubMed ID: 2713552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.